Lipid-based vectors for siRNA delivery

Journal of Drug Targeting

Volumn 20, Issue 9, 2012, Pages 724-735

  Zhang, Shubiao ^a,b   Zhi, Defu ^b   Huang, Leaf ^a  

^a University of North Carolina   (United States)

^b DALIAN NATIONALITIES UNIVERSITY   (China)

Author keywords

Gene therapy; Lipids; RNA interference; siRNA delivery

Indexed keywords

LIPID; LIPOSOME; SMALL INTERFERING RNA;

DRUG DELIVERY SYSTEM; GENE THERAPY; HUMAN; IN VITRO STUDY; NONHUMAN; PARTICLE SIZE; PH; PRIORITY JOURNAL; REVIEW;

ANIMALS; GENE SILENCING; GENETIC THERAPY; HUMANS; HYDROGEN-ION CONCENTRATION; LIPIDS; PARTICLE SIZE; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 84867613459     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2012.719232     Document Type: Review

References (107)

1. Adrian JE, Morselt HW, Suss R, Barnert S, Kok JW, Asgeirsdottir SA, Ruiters MH, Molema G, Kamps JA. (2010). Targeted SAINT-OSomes for improved intracellular delivery of siRNA and cytotoxic drugs into endothelial cells. J Control Release, 144, 341-349.
2. Ahmad A, Evans HM, Ewert K, George CX, Samuel CE, Safinya CR. (2005). New multivalent cationic lipids reveal bell curve for transfection efficiency versus membrane charge density: Lipid- DNA complexes for gene delivery. J Gene Med, 7, 739-748. (Pubitemid 40872860)
3. Akinc A, Goldberg M, Qin J, Dorkin JR, Gamba-Vitalo C, Maier M, Jayaprakash KN, Jayaraman M, Rajeev KG, Manoharan M, Koteliansky V, Rohl I, Leshchiner ES, Langer R, Anderson DG. (2009). Development of Lipidoid-siRNA Formulations for Systemic Delivery to the Liver. Mol Ther, 17, 872-879.
4. Akinc A, Zumbuehl A, Goldberg M, Leshchiner ES, Busini V, Hossain N, Bacallado SA, Nguyen DN, Fuller J, Alvarez R, Borodovsky A, Borland T, Constien R, de Fougerolles A, Dorkin JR, Narayanannair Jayaprakash K, Jayaraman M, John M, Koteliansky V, Manoharan M, Nechev L, Qin J, Racie T, Raitcheva D, Rajeev KG, Sah DW, Soutschek J, Toudjarska I, Vornlocher HP, Zimmermann TS, Langer R, Anderson DG. (2008). A combinatorial library of lipidlike materials for delivery of RNAi therapeutics. Nat Biotechnol, 26, 561-569. (Pubitemid 351668042)
5. Arpicco S, Canevari S, Ceruti M, Galmozzi E, Rocco F, Cattel, L. (2004). Synthesis characterization and transfection activity of new saturated and unsaturated cationic lipids. IL FARMACO, 59, 869-878. (Pubitemid 39488367)
6. Barreau C, Dutertre S, Paillard L, Osborne HB. (2006). Liposomemediated RNA transfection should be used with caution. RNA, 12, 1790-1793. (Pubitemid 44484251)
7. Beale G, Hollins AJ, Benboubetra M, Sohail M, Fox SP, Benter I, Akhtar S. (2003). Gene silencing nucleic acids designed by scanning arrays: Anti-EGFR activity of siRNA, ribozyme and DNA enzymes targeting a single hybridization-accessible region using the same delivery system. J Drug Target, 11, 449-456. (Pubitemid 38455831)
8. Bianco A, Bonadies F, Napolitano R, Ortaggi G. (2005). A simple approach to DC-cholesterol, its analogues and vitamin D-based cationic lipids for gene therapy. Lett Org Chem, 2, 79-82.
9. Bouxsein NF, McAllister CS, Ewert KK, Samuel CE, Safinya CR. (2007). Structure and gene silencing activities of monovalent and pentavalent cationic lipid vectors complexed with siRNA. Biochemistry, 46, 4785-4792. (Pubitemid 46651201)
10. Bouxsein NF, McAllister CS, Ewert KK, Samuel CE, Safinya CR. (2007). Structure and gene silencing activities of monovalent and pentavalent cationic lipid vectors complexed with siRNA. Biochemistry, 46, 4785-4792. (Pubitemid 46651201)
11. Ceballos C, Prata CA, Giorgio S, Garzino F, Payet D, Barthelemy P, Grinstaff MW, Camplo M. (2009). Cationic nucleoside lipids based on a 3-nitropyrrole universal base for siRNA delivery. Bioconjug Chem, 20, 193-196.
12. Cevc G, Richardsen H. (1999). Lipid vesicles and membrane fusion. Adv Drug Deliv Rev, 38, 207-232. (Pubitemid 29376575)
13. Chabaud P, Camplo M, Payet D, Serin G, Moreau L, Barthelemy P, Grinstaff MW. (2006). Cationic nucleoside lipids for gene delivery. Bioconjug Chem, 17, 466-472.
14. Chan CL, Majzoub R, Shirazi RS, Liang KS, Ewert KK, Safinya CR. (2012a). pH-Sensitive pegylated cationic lipid-DNA complexes for gene delivery: Transfection efficiency and live cell imaging studies. Biophys J, 102, 501-502a.
15. Chan CL, Majzoub RN, Shirazi RS, Ewert KK, Chen YJ, Liang KS, Safinya CR. (2012). Endosomal escape and transfection efficiency of PEGylated cationic liposome-DNA complexes prepared with an acid-labile PEG-lipid. Biomaterials, 33, 4928-4935.
16. Chen Y, Bathula SR, Li J, Huang L. (2010). Multifunctional nanoparticles delivering small interfering RNA and doxorubicin overcome drug resistance in cancer. J Biol Chem, 285, 22639-22650.
17. Chen Y, Bathula SR, Yang Q, Huang L. (2010). Targeted nanoparticles deliver siRNA to melanoma. J Invest Dermatol, 130, 2790-2798.
18. Chen Y, Zhu X, Zhang X, Liu B, Huang L. (2010). Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy. Mol Ther, 18, 1650-1656.
19. Chen Y, Sen J, Bathula SR, Yang Q, Fittipaldi R, Huang L. (2009). Novel cationic lipid that delivers siRNA and enhances therapeutic effect in lung cancer cells. Mol Pharm, 6, 696-705.
20. Chono S, Li SD, Conwell CC, Huang L. (2008). An efficient and low immunostimulatory nanoparticle formulation for systemic siRNA delivery to the tumor. J Control Release, 131, 64-69.
21. de Wolf HK, de Raad M, Snel C, van Steenbergen MJ, Fens MH, Storm G, Hennink WE. (2007). Biodegradable poly(2-dimethylamino ethylamino)phosphazene for in vivo gene delivery to tumor cells. Effect of polymer molecular weight. Pharm Res, 24, 1572-1580. (Pubitemid 46988226)
22. Elouahabi A, Ruysschaert JM. (2005). Formation and intracellular trafficking of lipoplexes and polyplexes. Mol Ther, 11, 336-347. (Pubitemid 40277310)
23. Ewert K, Ahmad A, Evans HM, Schmidt HW, Safinya CR. (2002). Efficient synthesis and cell-transfection properties of a new multivalent cationic lipid for nonviral gene delivery. J Med Chem, 45, 5023-5029. (Pubitemid 35278697)
24. Farhood H, Bottega R, Epand RM, Huang L. (1992). Effect of cationic cholesterol derivatives on gene transfer and protein kinase C activity. Biochim Biophys Acta, 1111, 239-246.
25. Farhood H, Serbina N, Huang L. (1995). The role of dioleoyl phosphatidylethanolamine in cationic liposome mediated gene transfer. Biochim Biophys Acta, 1235, 289-295.
26. Felgner PL, Gadek TR, Holm M, Roman R, Chan HS, Wenz M, Northrop JP, Ringold GM, Danielsen M. (1987). Lipofection: A highly efficient,lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci USA, 84, 7413-7417.
27. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. (1998). Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature, 391, 806-811. (Pubitemid 28099681)
28. Flynn MA, Casey DG, Todryk SM, Mahon BP. (2004). Efficient delivery of small interfering RNA for inhibition of IL-12p40 expression in vivo. J Inflamm (Lond), 1, 4.
29. Foged C, Nielsen HM, Frokjaer S. (2007). Liposomes for phospholipase A2 triggered siRNA release: Preparation and in vitro test. Int J Pharm, 331, 160-166. (Pubitemid 46216673)
30. Foged C. (2012). siRNA delivery with lipid-based systems: Promises and pitfalls. Curr Top Med Chem, 12, 97-107.
31. Gao K, Huang L. (2009). Nonviral methods for siRNA delivery. Mol Pharm, 6, 651-658.
32. Gao X, Huang L. (1996). Potentiation of cationic liposome-mediated gene delivery by polycations. Biochemistry, 35, 1027-1036. (Pubitemid 26034590)
33. Geisbert TW, Lee AC, Robbins M, Geisbert JB, Honko AN, Sood V, Johnson JC, de Jong S, Tavakoli I, Judge A, Hensley LE, Maclachlan I. (2010). Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: A proof-ofconcept study. Lancet, 375, 1896-1905.
34. Gilmore IR, Fox SP, Hollins AJ, Sohail M, Akhtar S. (2004). The design and exogenous delivery of siRNA for post-transcriptional gene silencing. J Drug Target, 12, 315-340. (Pubitemid 39294830)
35. Guo J, Bourre L, Soden DM, O'Sullivan GC, O'Driscoll C. (2011). Can non-viral technologies knockdown the barriers to siRNA delivery and achieve the next generation of cancer therapeutics? iotechnol Adv, 29, 402-417.
36. Heyes J, Palmer L, Bremner K, MacLachlan I. (2005). Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids. J Control Release, 107, 276-287. (Pubitemid 41316290)
37. Hornung V, Guenthner-Biller M, Bourquin C, Ablasser A, Schlee M, Uematsu S, Noronha A, Manoharan M, Akira S, de Fougerolles A, Endres S, Hartmann G. (2005). Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med, 11, 263-270. (Pubitemid 40460553)
38. Huang YH, Bao Y, Peng W, Goldberg M, Love K, Bumcrot DA, Cole G, Langer R, Anderson DG, Sawicki JA. (2009). Claudin-3 gene silencing with siRNA suppresses ovarian tumor growth and metastasis. Proc Natl Acad Sci USA, 106, 3426-3430.
39. Jana S, Chakraborty C, Nandi S, Deb JK. (2004). RNA interference: Potential therapeutic targets. Appl Microbiol Biotechnol, 65, 649-657. (Pubitemid 39506545)
40. Jiang S, Zhang Y. (2010). Upconversion nanoparticle-based FRET system for study of siRNA in live cells. Langmuir, 26, 6689-6694.
41. John M, Constien R, Akinc A, Goldberg M, Moon YA, Spranger M, Hadwiger P, Soutschek J, Vornlocher HP, Manoharan M, Stoffel M, Langer R, Anderson DG, Horton JD, Koteliansky V, Bumcrot D. (2007). Effective RNAi-mediated gene silencing without interruption of the endogenous microRNA pathway. Nature, 449, 745-747. (Pubitemid 47552094)
42. Judge AD, Sood V, Shaw JR, Fang D, McClintock K, MacLachlan I. (2005). Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol, 23, 457-462. (Pubitemid 41724921)
43. Juliano R, Alam MR, Dixit V, Kang H. (2008). Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides. Nucleic Acids Res, 36, 4158-4171. (Pubitemid 351984831)
44. Karagiannis TC, El-Osta A. (2005). RNA interference and potential therapeutic applications of short interfering RNAs. Cancer Gene Ther, 12, 787-795. (Pubitemid 43086280)
45. Kemphues KJ, Guo S. (1995). par-1, a gene required for establishing polarity in C. elegans embryos, encodes a putative Ser/Thr kinase that is asymmetrically distributed. Cell, 81, 611-620.
46. Khan A, Benboubetra M, Sayyed PZ, Ng KW, Fox S, Beck G, Benter IF, Akhtar S. (2004). Sustained polymeric delivery of gene silencing antisense ODNs, siRNA, DNAzymes and ribozymes: In vitro and in vivo studies. J Drug Target, 12, 393-404. (Pubitemid 39302465)
47. Khoury M, Louis-Plence P, Escriou V, Noel D, Largeau C, Cantos C, Scherman D, Jorgensen C, Apparailly F. (2006). Efficient new cationic liposome formulation for systemic delivery of small interfering RNA silencing tumor necrosis factor a in experimental arthritis. Arthritis Rheum, 54, 1867-1877. (Pubitemid 43877936)
48. Li CX, Parker A, Menocal E, Xiang S, Borodyansky L, Fruehauf JH. (2006). Delivery of RNA interference. Cell Cycle, 5, 2103-2109. (Pubitemid 44553744)
49. Li J, Chen YC, Tseng YC, Mozumdar S, Huang L. (2010). Biodegradable calcium phosphate nanoparticle with lipid coating for systemic siRNA delivery. J Control Release, 142, 416-421.
50. Li J, Yang Y, Huang L. (2012). Calcium phosphate nanoparticles with an asymmetric lipid bilayer coating for siRNA delivery to the tumor. J Control Release, 158, 108-114.
51. Li S, Huang L. (1997). In vivo gene transfer via intravenous administration of cationic lipid-protamine-DNA (LPD) complexes. Gene Ther, 4, 891-900. (Pubitemid 27437714)
52. Li SD, Chono S, Huang L. (2008). Efficient oncogene silencing and metastasis inhibition via systemic delivery of siRNA. Mol Ther, 16, 942-946. (Pubitemid 351587105)
53. Li SD, Chono S, Huang L. (2008). Efficient gene silencing in metastatic tumor by siRNA formulated in surface-modified nanoparticles. J Control Release, 126, 77-84.
54. Li SD, Huang L. (2006). Targeted delivery of antisense oligodeoxynucleotide and small interference RNA into lung cancer cells. Mol Pharm, 3, 579-588. (Pubitemid 44639135)
55. Li SD, Huang L. (2006). Surface-modified LPD nanoparticles for tumor targeting. Ann N Y Acad Sci, 1082, 1-8. (Pubitemid 44955442)
56. Li SD, Huang L. (2009). Nanoparticles evading the reticuloendothelial system: Role of the supported bilayer. Biochim Biophys Acta, 1788, 2259-2266.
57. Liu D, Hu J, Qiao W, Li Z, Zhang S, Cheng L. (2005). Synthesis of carbamate-linked lipids for gene delivery. Bioorg Med Chem Lett, 15, 3147-3150. (Pubitemid 40755212)
58. Liu D, Hu J, Qiao W, Li Z, Zhan S, Cheng L. (2005). Synthesis and characterization of a series of carbamate-linked cationic lipids for gene delivery. Lipids, 40, 839-848. (Pubitemid 41393260)
59. Liu D, Qiao W, Li Z, Chen Y, Cui X, Li K, Yu L, Yan K, Zhu L, Guo Y, Cheng L. (2008). Structure-function relationship research of glycerol backbone-based cationic lipids for gene delivery. Chem Biol Drug Des, 71, 336-344. (Pubitemid 351347795)
60. Liu F, Huang L. (2002). Development of non-viral vectors for systemic gene delivery. J Control Release, 78, 259-266. (Pubitemid 34081870)
61. Lorenz C, Hadwiger P, John M, Vornlocher HP, Unverzagt C. (2004). Steroid and lipid conjugates of siRNAs to enhance cellular uptake and gene silencing in liver cells. Bioorg Med Chem Lett, 14, 4975-4977. (Pubitemid 39165605)
62. Love KT, Mahon KP, Levins CG, Whitehead KA, Querbes W, Dorkin JR, Qin J, Cantley W, Qin LL, Racie T, Frank-Kamenetsky M, Yip KN, Alvarez R, Sah DW, de Fougerolles A, Fitzgerald K, Koteliansky V, Akinc A, Langer R, Anderson DG. (2010). Lipid-like materials for low-dose, in vivo gene silencing. Proc Natl Acad Sci USA, 107, 1864-1869.
63. Lv H, Zhang S, Wang B, Cui S, Yan J. (2006). Toxicity of cationic lipids and cationic polymers in gene delivery. J Control Release, 114, 100-109. (Pubitemid 44128621)
64. Ma B, Zhang S, Jiang H, Zhao B, Lv H. (2007). Lipoplex morphologies and their influences on transfection efficiency in gene delivery. J Control Release, 123, 184-194. (Pubitemid 350007826)
65. Mahon KP, Love KT, Whitehead KA, Qin J, Akinc A, Leshchiner E, Leshchiner I, Langer R, Anderson DG. (2010). Combinatorial approach to determine functional group effects on lipidoidmediated siRNA delivery. Bioconjug Chem, 21, 1448-1454.
66. Malone RW, Felgner PL, Verma IM. (1989). Cationic liposome-mediated RNA transfection. Proc Natl Acad Sci USA, 86, 6077-6081. (Pubitemid 19210605)
67. Mamot C, Drummond DC, Noble CO, Kallab V, Guo Z, Hong K, Kirpotin DB, Park JW. (2005). Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. Cancer Res, 65, 11631-11638. (Pubitemid 41821723)
68. Mevel M, Kamaly N, Carmona S, Oliver MH, Jorgensen MR, Crowther C, Salazar FH, Marion PL, Fujino M, Natori Y, Thanou M, Arbuthnot P, Yaouanc JJ, Jaffres PA, Miller AD. (2010). DODAG; a versatile new cationic lipid that mediates efficient delivery of pDNA and siRNA. J Control Release, 143, 222-232.
69. Midoux P, Pichon C, Yaouanc JJ, Jaffres PA. (2009). Chemical vectors for gene delivery: A current review on polymers, peptides and lipids containing histidine or imidazole as nucleic acids carriers. Br J Pharmacol, 157, 166-178.
70. Morille M, Passirani C, Vonarbourg A, Clavreul A, Benoit JP. (2008). Progress in developing cationic vectors for non-viral systemic gene therapy against cancer. Biomaterials, 29, 3477-3496.
71. Morrissey DV, Lockridge JA, Shaw L, Blanchard K, Jensen K, Breen W, Hartsough K, Machemer L, Radka S, Jadhav V, Vaish N, Zinnen S, Vargeese C, Bowman K, Shaffer CS, Jeffs LB, Judge A, MacLachlan I, Polisky B. (2005). Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol, 23, 1002-1007. (Pubitemid 41114035)
72. Oh YK, Park TG. (2009). siRNA delivery systems for cancer treatment. Adv Drug Deliv Rev, 61, 850-862.
73. Omidi Y, Hollins AJ, Benboubetra M, Drayton R, Benter IF, Akhtar S. (2003). Toxicogenomics of non-viral vectors for gene therapy: A microarray study of lipofectin- and oligofectamine-induced gene expression changes in human epithelial cells. J Drug Target, 11, 311-323. (Pubitemid 38081335)
74. Ozpolat B, Sood AK, Lopez-Berestein G. (2010). Nanomedicine based approaches for the delivery of siRNA in cancer. J Intern Med, 267, 44-53.
75. Pan X, Thompson R, Meng X, Wu D, Xu L. (2011). Tumor-targeted RNAinterference: Functional non-viral nanovectors. Am J Cancer Res, 1, 25-42.
76. Park K. (2010). Systemic siRNA delivery using biocompatible calcium phosphate nanoparticles. J Control Release, 142, 295.
77. Perkel JM. (2009). RNAi therapeutics: A two-year update. Science, 326, 454-456.
78. Pirollo KF, Rait A, Zhou Q, Hwang SH, Dagata JA, Zon G, Hogrefe RI, Palchik G, Chang EH. (2007). Materializing the potential of small interfering RNA via a tumor-targeting nanodelivery system. Cancer Res, 67, 2938-2943. (Pubitemid 46724828)
79. Romoren K, Thu BJ, Bols NC, Evensen O. (2004). Transfection efficiency and cytotoxicity of cationic liposomes in salmonid cell lines of hepatocyte and macrophage origin. Biochim Biophys Acta, 1663, 127-134. (Pubitemid 38625587)
80. Rossin R, Pan D, Qi K, Turner JL, Sun X, Wooley KL, Welch MJ. (2005). 64Cu-labeled folate-conjugated shell cross-linked nanoparticles for tumor imaging and radiotherapy: Synthesis, radiolabeling, and biologic evaluation. J Nucl Med, 46, 1210-1218.
81. Sato A, Takagi M, Shimamoto A, Kawakami S, Hashida M. (2007). Small interfering RNA delivery to the liver by intravenous administration of galactosylated cationic liposomes in mice. Biomaterials, 28, 1434-1442. (Pubitemid 44959042)
82. Scales CW, Huang F, Li N, Vasilieva YA, Ray J, Convertine AJ, McCormick CL. (2006). Corona-stabilized interpolyelectrolyte complexes of siRNA with non-immunogenic, hydrophilic/cationic block copolymers prepared by aqueous RAFT polymerization. Macromolecules, 39, 6871-6881. (Pubitemid 44625919)
83. Schroeder A, Levins CG, Cortez C, Langer R, Anderson DG. (2010). Lipid-based nanotherapeutics for siRNA delivery. J Intern Med, 267, 9-21.
84. Semple SC, Akinc A, Chen J, Sandhu AP, Mui BL, Cho CK, Sah DW, Stebbing D, Crosley EJ, Yaworski E, Hafez IM, Dorkin JR, Qin J, Lam K, Rajeev KG, Wong KF, Jeffs LB, Nechev L, Eisenhardt ML, Jayaraman M, Kazem M, Maier MA, Srinivasulu M, Weinstein MJ, Chen Q, Alvarez R, Barros SA, De S, Klimuk SK, Borland T, Kosovrasti V, Cantley WL, Tam YK, Manoharan M, Ciufolini MA, Tracy MA, de Fougerolles A, MacLachlan I, Cullis PR, Madden TD, Hope MJ. (2010). Rational design of cationic lipids for siRNA delivery. Nat Biotechnol, 28, 172-176.
85. Sheng R, Luo T, Zhu Y, Li H, Sun J, Chen S, Sun W, Cao A. (2011). The intracellular plasmid DNA localization of cationic reducible cholesterol-disulfide lipids. Biomaterials, 32, 3507-3519.
86. Shirazi RS, Ewert KK, Leal C, Majzoub RN, Bouxsein NF, Safinya CR. (2011). Synthesis and characterization of degradable multivalent cationic lipids with disulfide-bond spacers for gene delivery. Biochim Biophys Acta, 1808, 2156-2166.
87. Sioud M, Sorensen DR. (2003). Cationic liposome-mediated delivery of siRNAs in adult mice. Biochem Biophys Res Commun, 312, 1220-1225. (Pubitemid 37490947)
88. Sorgi FL, Bhattacharya S, Huang L. (1997). Protamine sulfate enhances lipid-mediated gene transfer. Gene Ther, 4, 961-968. (Pubitemid 27437722)
89. Sparks J, Slobodkin G, Matar M, Congo R, Ulkoski D, Rea-Ramsey A, Pence C, Rice J, McClure D, Polach KJ, Brunhoeber E, Wilkinson L, Wallace K, Anwer K, Fewell JG. (2012). Versatile cationic lipids for siRNA delivery. J Control Release, 158, 269-276.
90. Spelios M, Nedd S, Matsunaga N, Savva M. (2007). Effect of spacer attachment sites and pH-sensitive headgroup expansion on cationic lipid-mediated gene delivery of three novel myristoyl derivatives. Biophys Chem, 129, 137-147. (Pubitemid 47198367)
91. Tan SJ, Kiatwuthinon P, Roh YH, Kahn JS, Luo D. (2011). Engineering Nanocarriers for siRNA Delivery. Small, 7, 841-856.
92. Tao W, Davide JP, Cai M, Zhang GJ, South VJ, Matter A, Ng B, Zhang Y, Sepp-Lorenzino L. (2010). Noninvasive imaging of lipid nanoparticle-mediated systemic delivery of small-interfering RNA to the liver. Mol Ther, 18, 1657-1666.
93. Verma UN, Surabhi RM, Schmaltieg A, Becerra C, Gaynor RB. (2003). RNAs directed against betacatenin inhibit the in vitro and in vivo growth of colon cancer cells. Clin Cancer Res, 9, 1291-1300. (Pubitemid 36418379)
94. Sorensen DR, Leirdal M, Sioud M. (2003). Gene silencing by systemic delivery of synthetic siRNAs in adult mice. J Mol Biol, 327, 761-766. (Pubitemid 36315917)
95. Wagner E, Cotten M, Foisner R, Birnstiel ML. (1991). Transferrinpolycation- DNA complexes: The effect of polycations on the structure of the complex and DNA delivery to cells. Proc Natl Acad Sci USA, 88, 4255-4259. (Pubitemid 21914518)
96. Wang AZ, Langer R, Farokhzad OC. (2012). Nanoparticle delivery of cancer drugs. Annu Rev Med, 63, 185-198.
97. Whitehead KA, Langer R, Anderson DG. (2009). Knocking down barriers: Advances in siRNA delivery. Nat Rev Drug Discov, 8, 129-138.
98. Whitehead KA, Sahay G, Li GZ, Love KT, Alabi CA, Ma M, Zurenko C, Querbes W, Langer RS, Anderson DG. (2011). Synergistic silencing: Combinations of lipid-like materials for efficacious siRNA delivery. Mol Ther, 19, 1688-1694.
99. Woodle MC, Scaria P. (2001). Cationic liposomes and nucleic acids. Curr Opin Colloid Interface Sci, 6, 78-84. (Pubitemid 32233070)
100. Yang Y, Li J, Liu F, Huang L. (2012). Systemic delivery of siRNA via LCP nanoparticle efficiently inhibits lung metastasis. Mol Ther, 20, 609-615.
101. Zabner J. (1997). Cationic lipids used in gene transfer. Adv Drug Deliv Rev, 27, 17-28. (Pubitemid 27301394)
102. Zamore PD, Tuschl T, Sharp PA, Bartel DP. (2000). RNAi: Doublestranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell, 101, 25-33.
103. Zhang S, Xu Y, Wang B, Qiao W, Liu D, Li Z. (2004). Cationic compounds used in lipoplexes and polyplexes for gene delivery. J Control Release, 100, 165-180. (Pubitemid 39491269)
104. Zhao YN, Zhi DF, Zhang SB. (2011). Cationic liposomes in different structural levels for gene delivery. In: Non-viral Gene Therapy. Yuan XB (Ed). Rijeka, Croatia: InTech, 293-318.
105. Zhdanov RI, Podobed OV, Vlassov VV. (2002). Cationic lipid- DNA complexes-lipoplexes-for gene transfer and therapy. Bioelectrochemistry, 58, 53-64. (Pubitemid 36160467)
106. Zimmermann TS, Lee AC, Akinc A, Bramlage B, Bumcrot D, Fedoruk MN, Harborth J, Heyes JA, Jeffs LB, John M, Judge AD, Lam K, McClintock K, Nechev LV, Palmer LR, Racie T, Rohl I, Seiffert S, Shanmugam S, Sood V, Soutschek J, Toudjarska I, Wheat AJ, Yaworski E, Zedalis W, Koteliansky V, Manoharan M, Vornlocher HP, MacLachlan I. (2006). RNAi-mediated gene silencing in nonhuman primates. Nature, 441, 111-114.
107. Zuhorn IS, Bakowsky U, Polushkin E, Visser WH, Stuart MC, Engberts JB, Hoekstra D. (2005). Nonbilayer phase of lipoplex-membrane mixture determines endosomal escape of genetic cargo and transfection efficiency. Mol Ther, 11, 801-810. (Pubitemid 40567984)